Journal Home
Search for

Volume 582, Issue 6, Pages 844-847 (19 March 2008)


View previous. 3 of 30 View next.

New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications

Edited by Barry Halliwell

Anna Rosa Sannellaa, Angela Casinib, Chiara Gabbianib, Luigi MessoribCorresponding Author Informationemail address, Anna Rita Biliac, Francesco Franco Vincieric, Giancarlo Majoria, Carlo Severinia

Received 28 January 2008; received in revised form 8 February 2008; accepted 14 February 2008. published online 21 February 2008.

Abstract 

The clinically established gold-based antiarthritic drug auranofin (AF) manifests a pronounced reactivity toward thiol and selenol groups of proteins. In particular, AF behaves as a potent inhibitor of mammalian thioredoxin reductases causing severe intracellular oxidative stress. Given the high sensitivity of Plasmodium falciparum to oxidative stress, we thought that auranofin might act as an effective antimalarial agent. Thus, we report here new experimental results showing that auranofin and a few related gold complexes strongly inhibit P. falciparum growth in vitro. The observed antiplasmodial effects probably arise from direct inhibition of P. falciparum thioredoxin reductase. The above findings and the safe toxicity profile of auranofin warrant rapid evaluation of AF for malaria treatment in animal models.

a Department of Infectious, Parasitic and Immunomediated Diseases, Vector-Borne Diseases and International Health Section, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy

b Department of Chemistry, University of Florence, Via della Lastruccia 3, 50019 Sesto Fiorentino, Florence, Italy

c Department of Pharmaceutical Sciences, University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Florence, Italy

Corresponding Author InformationCorresponding author. Fax: +39 0 55 457 3385.

PII: S0014-5793(08)00136-1

doi:10.1016/j.febslet.2008.02.028


View previous. 3 of 30 View next.